New drug aims to keep aggressive blood cancer at bay
NCT ID NCT07509151
Summary
This study is testing whether a drug called surovatamig can help control a specific, harder-to-treat type of blood cancer (CLL/SLL) after patients finish their first round of standard therapy. It will compare giving the drug as a follow-up 'maintenance' treatment against simply watching patients closely. The goal is to see if the drug can delay the cancer from coming back or getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKAEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WITH UNMUTATED IGHV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
Adelaide, 5000, Australia
-
Research Site
Fitzroy, 3065, Australia
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Calgary, Alberta, T2N 5G2, Canada
-
Research Site
Hamilton, Ontario, L8V 5C2, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
Istanbul, 34899, Turkey (Türkiye)
-
Research Site
Mezitli, 33200, Turkey (Türkiye)
-
Research Site
Edinburgh, EH4 2XU, United Kingdom
-
Research Site
Leeds, LS9 7TF, United Kingdom
-
Research Site
London, SE5 9RS, United Kingdom
-
Research Site
Oxford, OX3 7LE, United Kingdom
-
Research Site
Sutton, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.